BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32746640)

  • 1. Proteasome inhibition for the treatment of glioblastoma.
    Roth P; Mason WP; Richardson PG; Weller M
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1133-1141. PubMed ID: 32746640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
    Manton CA; Johnson B; Singh M; Bailey CP; Bouchier-Hayes L; Chandra J
    Sci Rep; 2016 Jan; 6():18953. PubMed ID: 26804704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
    Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.
    Areeb Z; Stylli SS; Ware TM; Harris NC; Shukla L; Shayan R; Paradiso L; Li B; Morokoff AP; Kaye AH; Luwor RB
    Med Oncol; 2016 May; 33(5):53. PubMed ID: 27098175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
    Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
    Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
    Boccellato C; Kolbe E; Peters N; Juric V; Fullstone G; Verreault M; Idbaih A; Lamfers MLM; Murphy BM; Rehm M
    Cell Death Dis; 2021 Jun; 12(7):647. PubMed ID: 34168123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.
    Bullova P; Cougnoux A; Marzouca G; Kopacek J; Pacak K
    Endocrinology; 2017 Oct; 158(10):3097-3108. PubMed ID: 28938421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor.
    Nakano Y; Takadera M; Miyazaki M; Qiao Z; Nakajima K; Noguchi R; Oyama R; Kimura Y; Okuhiro Y; Yamasaki K; Kunihiro N; Fukushima H; Inoue T; Hara J; Ozawa T; Kondo T; Ichimura K
    Hum Cell; 2021 Jan; 34(1):271-278. PubMed ID: 32997328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
    Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
    Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
    Chao A; Wang TH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):3-8. PubMed ID: 26927239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marizomib, a potent second generation proteasome inhibitor from natural origin.
    Ma L; Diao A
    Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Pédeboscq S; L'Azou B; Passagne I; De Giorgi F; Ichas F; Pometan JP; Cambar J
    J Exp Ther Oncol; 2008; 7(2):99-111. PubMed ID: 18771084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
    Zhang X; Li W; Wang C; Leng X; Lian S; Feng J; Li J; Wang H
    Mol Cell Biochem; 2014 Jan; 385(1-2):265-75. PubMed ID: 24104452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
    Citrin R; Foster JB; Teachey DT
    Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.